





RealRate

PHARMACEUTICAL 2023

UroGen Pharma Ltd.
Rank 378 of 446



The relative strengths and weaknesses of UroGen Pharma Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UroGen Pharma Ltd. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 20% points. The greatest weakness of UroGen Pharma Ltd. is the variable Assets, Current, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is -146%, being 189% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	128,907
Cost of Goods Sold	7,654
Intangible Assets	0
Liabilities, Current	23,916
Liabilities, Non-Current	99,123
Other Assets	5,415
Other Compr. Net Income	-82
Other Expenses	31,752
Other Liabilities	101,941
Other Net Income	0
Other Revenues	65,367
Property and Equipment	1,297
Research and Development	52,906
Selling, General and Administrative Expense	82,838

Output Variable	Value in 1000 USD
Assets	135,619
Liabilities	224,980
Expenses	175,150
Revenues	65,367
Stockholders Equity	-89,361
Net Income	-109,783
Comprehensive Net Income	-109,824
Economic Capital Ratio	-146%